Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial
Journal of Clinical Lipidology Nov 10, 2017
Stroes ESG, et al. - In this study, researchers compared the intermediate dose of omega-3 carboxylic acids (OM3-CA, 2 g daily) to olive oil 2 g daily for efficacy and safety in reducing serum triglyceride (TG) and lipid concentrations in patients with severe hypertriglyceridemia (SHTG). Findings revealed that in addition to resulting in significant lowering in TG and non-high-density lipoprotein cholesterol (non-HDL-C) concentrations, an intermediate dose of OM3-CA (2 g daily) may benefit individuals at risk of acute pancreatitis and cardiovascular disease.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries